Edgar Filing: IMMUNOGEN INC - Form 4

IMMUNOGEN INC Form 4 February 01, 2016 FORM 4 The form 5 soligations <i>See</i> Instruction 1(b). IMMUNOGEN INC Form 4 or Form 5 obligations <i>See</i> Instruction 1(b). IMMUNOGEN INC Form 4 or Form 5 obligations <i>See</i> Instruction 1(b). IMB 2325-027 <i>Statement of changes in Beneficial ownership of Securities Exchange Act of 1934</i> , Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 1(b). IMB 2325-027 <i>Statement of changes in Beneficial ownership of all of the Securities Exchange Act of 1934</i> , Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 1(b).					
1. Name and Address of Reporting Person LAMBERT JOHN	2. Issuer Name and Ticker or Trading Symbol IMMUNOGEN INC [IMGN]	5. Relationship of Reporting Person(s) to Issuer			
(Last) (First) (Middle) C/O IMMUNOGEN, INC., 830 WINTER STREET	3. Date of Earliest Transaction (Month/Day/Year) 02/01/2016	(Check all applicable) <u></u> Director <u></u> 10% Owner <u></u> Officer (give title <u></u> Other (specify below) Executive Vice President			
(Street)	4. If Amendment, Date Original Filed(Month/Day/Year)	 6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting 			
WALTHAM, MA 02451		Person			
(City) (State) (Zip)	Table I - Non-Derivative Securitie	s Acquired, Disposed of, or Beneficially Owned			
(Instr. 3) any (Mon	tion Date, if Transaction(A) or Disposed of Code (Instr. 3, 4 and 5) (h/Day/Year) (Instr. 8) (A) or				
Common 02/01/2016(2) Stock		3.19 110,746 D			
Common 02/01/2016(2) Stock	S 3,889 D 8. (1)	2209 106,857 D			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: IMMUNOGEN INC - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisab Expiration Date (Month/Day/Year		7. Title and <i>J</i> Underlying S (Instr. 3 and	Securities
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 3.19	02/01/2016		М	3,889	06/08/2007 <u>(3)</u>	06/08/2016	Common Stock	3,889

Reporting Owners

Reporting Owner Name / Address			Relationships	
r U	Director	10% Owner	Officer	Other
LAMBERT JOHN C/O IMMUNOGEN, INC. 830 WINTER STREET WALTHAM, MA 02451			Executive Vice President	
Signatures				

Signatures

in fact	02/01/2016

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Weighted average price of shares sold.
- (2) The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan executed by the reporting person on February 20, 2015.
- (3) Exercisable as to 11,667 shares commencing on June 8, 2007, 11,667 shares commencing on June 8, 2008, and 11,666 shares commencing on June 8, 2009.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.